Pharmacokinetic (PK) Bridging ELISA

Protocol

PK - Avelumab

For Use with Anti-Avelumab Monoclonal Antibodies Catalog #TZA041 and #TZA040P

This method provides a procedure for carrying out a PK ELISA with Anti-Avelumab Antibodies, #TZA041 (capture antibody) and HRP-conjugated #TZA040P (detection antibody), and using avelumab for the standard curve. The method should always be used in conjunction with product and batch specific information provided with each vial (see product datasheets). This protocol will need to be adjusted for use with different detection methods and immunoassay technology platforms.

Reagents

- BSA (Sigma-Aldrich, #A7906)
- HISPEC Assay Diluent (#BUF049)
- Human Serum (Sigma-Aldrich, #H4522)
- PBS
 - 136 mM NaCl
 - 2.68 mM KCl
 - 8.1 mM Na₂HPO₄
 - 1.46 mM KH₂PO₄
- PBST
 - PBS with 0.05% Tween 20 (Merck Millipore, #817072)

QuantaBlu Fluorogenic Peroxidase Substrate (Thermo Fisher Scientific, #15169)

Materials:

 384-well microtiter plate, black, square flat-bottom wells, for example, Black 384-Well Immuno Plates (Thermo Fisher Scientific, #460518) HISPEC Assay Diluent (#BUF049)

Fluorescence plate reader

96-well plates can be used instead of 384-well plates (black, flat-bottom wells), for example, Black 96-Well Immuno Plates (Thermo Fisher Scientific, #460518). For the 96-well format, use 100 μ l (instead of 20 μ l) of antigen, antibodies, or substrate and 300 μ l for the blocking step.

Method:

- Prepare the capture Anti-Avelumab Antibody #TZA041 (AbD40521ad) at 1 μg/ml in PBS. Coat the required number of wells of a 384-well microtiter plate with 20 μl per well of the prepared capture antibody, and incubate overnight at 4°C.
- 2. Wash the microtiter plate five times (5x) with PBST.
- 3. Block the microtiter plate by adding 100 µl 5% BSA in PBST to each well, and then incubate for 1 hr at RT.
- 4. Wash the microtiter plate 5x with PBST.
- 5. For the standard curve, prepare a dilution series of avelumab in 10% human serum in PBST in triplicate. Final concentration of avelumab should cover the range from 0.01 ng/ml to 10,000 ng/ml. Include a zero avelumab concentration as the background value.
- Add 20 µl of avelumab dilution per well (in triplicate for each standard recommended). Add 20 µl of each test sample to the other wells (in triplicate for each sample recommended). Incubate for 1 hr at RT.
- 7. Wash the microtiter plate 5x with PBST.
- To each well, add 20 µl HRP conjugated detection Anti-Avelumab Antibody, #TZA040P (AbD40519pap), at 0.5 µg/ml in HISPEC Assay Diluent. Incubate for 1 hr at RT.
- 9. Wash the microtiter plate 10x with PBST.
- 10. Add 20 µl QuantaBlu Fluorogenic Peroxidase Substrate to each well and measure the fluorescence after 30 min.



BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.



Bio-Rad Laboratories, Inc.

Life Science Group
 Website
 bio-rad.com
 USA 1 800 424 6723
 Australia 61 2 9914 2800
 Australia 00 800 00 24 67 23
 Belgium 00 800 00 24 67 23
 Brazil 4003 0399

 Canada 1 905 364 3435
 China 86 21 6169 8500
 Czech Republic 00 800 00 24 67 23
 Denmark 00 800 00 24 67 23
 Finland 00 800 00 24 67 23

 France 00 800 00 24 67 23
 Germany 00 800 00 24 67 23
 Hong Kong 852 2789 3300
 Hungary 00 800 00 24 67 23
 India 91 124 4029300
 Israel 0 3 9636050

 Italy 00 800 00 24 67 23
 Japan 81 3 6361 7000
 Kore 82 080 007 7373
 Luxembourg 00 800 00 24 67 23
 Mexico 52 555 488 7670

 The Netherlands 00 800 00 24 67 23
 Norway 00 800 00 24 67 23
 Portugal 00 800 00 24 67 23
 Portugal 00 800 00 24 67 23

 Russian Federation 00 800 00 24 67 23
 Singapore 65 6415 3188
 South Africa 00 800 00 24 67 23
 Spain 00 800 00 24 67 23
 Sweden 00 800 00 24 67 23

 Switzerland 00 800 00 24 67 23
 Taiwan 886 2 2578 7189
 Thailand 66 2 651 8311
 United Arab Emirates 36 1 459 6150
 United Kingdom 00 800 00 24 67 23

 (\mathbf{i})